Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical giant Bristol-Myers Squibb
With that in mind, let's take a closer look at Bristol-Myers' business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||New York (1887)|
|Market Cap||$54.7 billion|
|Trailing-12-Month Revenue||$20.5 billion|
|Management||CEO Lamberto Andreotti
CFO Charles Bancroft
|Return on Equity (average, past 3 years)||30.9%|
|Cash/Debt||$5.0 billion / $5.4 billion|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 94% of the 1,799 members who have rated Bristol-Myers believe the stock will outperform the S&P 500 going forward.
It is my belief that Bristol will outperform in the mid/long term due to its juicy and sustainable dividend, its smaller market cap when compared to companies like Merck or Pfizer, its wonderful return on equity and operating margins which show it has strong profitability and management. Also, its cash of [$5.03B] could just about pay off its debt [$5.42B] if needed. ... Bristol also has a strong current ratio of 1.63. Shares are also trading below their 50 and 200 day moving averages, making entering a new position even more promising.
If you want market-beating returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Bristol-Myers may not be your top choice.
If that's the case, we've compiled a special free report for investors called "Secure Your Future With 9 Rock-Solid Dividend Stocks," which uncovers several other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.